BioCryst Pharmaceuticals | BCRX - 市值

股票价格
9.56
每天变化
-0.33 -3.34%
每月一次
12.60%
每年
40.18%
Q2 预测
9.30


金融业
股票价格
USD
资产
USD 514.16M
现金及等价物
USD 335.91M
销售成本
USD 9.52M
流动资产
USD 404.35M
流动负债
USD 196.07M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -119.15M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 428.67M
市值
USD 1.98B
净收入
USD 245.85M
营业费用
USD 146.17M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.4M
贸易债权人
USD 15.83M
应收帐款人
USD 106.82M


市值 更改 日
Alnylam Pharmaceuticals USD 52.54B 7.24B 2025-12
BioCryst Pharmaceuticals USD 1.66B 64M 2025-12
Chugai Pharma JPY 13.84T 3.01T 2025-12
Daiichi Sankyo JPY 6.34T 62.51B 2025-12
DBV Technologies USD 274M 17M 2025-09
Enanta Pharmaceuticals USD 122M 98M 2024-12
Gilead Sciences USD 152.28B 14.55B 2025-12
GlaxoSmithKline GBP 74.36B 10.31B 2025-12
Glaxosmithkline GBP 99.93B 13.05B 2025-12
Incyte USD 19.39B 2.83B 2025-12
Ionis Pharmaceuticals USD 12.81B 2.39B 2025-12
Karyopharm Therapeutics USD 652M 517M 2026-04
Neurocrine Biosciences USD 14.14B 218M 2025-12
Novavax USD 1.09B 316M 2025-12
PTC Therapeutics USD 6.1B 1.22B 2025-12
Regeneron Pharmaceuticals USD 81.12B 21.53B 2025-12
Roche Holding CHF 266.34B 55.46B 2025-12
Sarepta Therapeutics USD 2.26B 238M 2025-12
Ultragenyx Pharmaceutical USD 2.22B 680M 2025-12
Vertex Pharmaceuticals USD 115.03B 14.61B 2025-12